GSK_Annual_Report_2021

Financial Statements GlaxoSmithKline Pharmaceuticals Limited 172 ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 A. CASH FLOWS FROM OPERATING ACTIVITIES Profit before exceptional items and tax 723,09.52 647,24.62 Adjustments for : Loss / (Gain) on disposal of property, plant and equipment (net) 5.88 (2,33.36) Interest income (110,57.49) (76,20.55) Finance costs 3,53.14 6,33.55 Depreciation and amortisation expense 79,28.36 82,67.77 Allowance for doubtful debts and advances 2,06.05 3,17.00 Provision written back - (47.32) Operating Profit before working capital changes 697,45.46 660,41.71 Change in operating assets and liabilities (Increase) in inventories (46,79.30) (67,71.67) (Increase) in trade receivables (99,93.42) (4.97) (Increase) / Decrease in other assets (11,70.61) 148,57.26 Increase / (Decrease) in trade payables 107,40.97 (48,22.97) Increase in provisions 27,08.09 12,77.16 Increase / (Decrease) in other liabilities 69,70.28 (1,27.99) Cash generated from operations 743,21.47 704,48.53 Income taxes paid (net of refunds) (146,96.18) (185,88.43) Cash inflow from operating activities before exceptional items 596,25.29 518,60.10 Exceptional items: Sale of brands - 50.69 Payment of Associated cost to impairment (7,03.09) (7,13.89) Payment of redundancy cost (11,30.59) (27,63.21) Income taxes on Exceptional items 0.93 6,16.28 Net cash generated from operating activities A 577,92.54 490,49.97 B. CASH FLOWS FROM INVESTING ACTIVITIES Payments to acquire property, plant and equipment and other intangible assets (44,22.66) (155,89.81) Proceeds from sale of property, plant and equipment 67.20 3,49.96 Margin money deposits 14.33 29.81 Investment in bank deposits (having original maturity more than 3 months but less than 12 months) (3378,23.00) (1141,00.00) Redemption / maturity of bank deposits (having original maturity more than 3 months but less than 12 months) 3603,23.00 1233,00.00 Interest received 55,00.34 65,27.11 Changes in earmarked balances 57.98 1,80.70 Cash inflow from investing activities before exceptional items 237,17.19 6,97.77 Consolidated Cash Flow Statement for the year ended March 31, 2021